Abstract
Document review practices in the research and development functions of many pharmaceutical companies can be frustrating and inefficient, at least in part because these practices are poorly managed. Although the literature on review practice is fairly robust, there is a disjuncture between what researchers know and how reviewers work. The author draws on his experience as a consultant and trainer to many pharmaceutical companies to outline the causes and effects of poor review practice. He offers recommendations to enhance the value and increase the efficiency of reviews.
Get full access to this article
View all access options for this article.
